

BACIL PHARMA LIMITED

Regd. Off.: G2 & G3, Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400 099
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

21st January, 2025

To
The Bombay Stock Exchange Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Dear Sir/ Madam,

Ref: - Scrip Code: 524516

Sub: Outcome of Board Meeting

We are to inform the exchange that the meeting of Board of Directors of the M/s. Bacil Pharma Limited has been duly convened on Tuesday, 21st January, 2024 at 71, Laxmi Building, Sir P. M. Road, Fort, Mumbai – 400 001 and the Board has transacted following items:

- Considered and approved the Un-audited Financial Results along with Limited Review Report of the Company for the Quarter and Nine Months ended 31st December, 2024.
- Other routine business with the permission of the Chair.

Please note that the Meeting of the Board of Directors commenced at 5.00 P.M. and concluded at 6:25 P.M.

Kindly take the note of the same and update on your records.

For **Bacil Pharma Ltd.**



Mehul Hasmukhbhai Shah
Chairman & Director
DIN: 10753865

BACIL PHARMA LIMITED

CIN : {L24200MH1987PLC043427}

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2024

(Amount in Lakhs)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	-	-	-	-	-	-
	Other income	0.25	56.04	3.29	57.37	10.93	13.05
	Total revenue	0.25	56.04	3.29	57.37	10.93	13.05
2	Expenses						
	Employee benefits expense	3.82	3.91	3.44	10.14	6.33	9.89
	Depreciation and amortization expense	-	0.04	0.05	0.07	0.15	0.20
	Other expenses	2.58	3.34	2.24	7.96	6.30	8.86
	Total expenses	6.40	7.29	5.73	18.17	12.79	18.94
3	Profit/(Loss) before Exceptional Items & Tax	(6.15)	48.74	(2.44)	39.20	(1.85)	(5.90)
4	Tax expense:						
	Current tax	-	-	-	-	-	-
	Deferred tax	-	(0.34)	0.00	(0.34)	0.01	(0.01)
5	Profit/(Loss) from ordinary activities after tax	(6.15)	48.40	(2.44)	38.85	(1.85)	(5.91)
6	Other Comprehensive Income (OCI)						
	<u>Item that will not be reclassified to profit or loss</u>						
	Gain/(Loss) on recognised on fair valuation of Financial Assets	1.83	(29.78)	3.36	5.35	22.02	23.36
	Income tax relating to these items	(0.48)	7.74	(0.87)	(1.39)	(5.72)	(6.07)
	Total Other Comprehensive Income (OCI)	1.35	(22.04)	2.49	3.96	16.29	17.28
	Profit/(Loss) for the Period	(4.80)	26.37	0.05	42.82	14.44	11.38
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	589	589	589	589	589	589
7	Earning Per Share (EPS) (Not annualised)						
	Basic	(0.10)	0.82	(0.04)	0.66	(0.03)	(0.10)
	Diluted	(0.10)	0.82	(0.04)	0.66	(0.03)	(0.10)

Notes:

- The Above Financial Results were reviewed by the audit committee and approved by the Board of Directors of the company at their Meeting held on 21/01/2025. The Statutory Auditor have expressed an unmodified opinion. The review report has been filled with stock exchange and is available on the company's website.
- The Financial results have been prepared in accordance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- The company has no separate reportable segment therefore in the context of Ind AS 108, disclosure of segment information is not applicable.
- Previous quarter figures have been regrouped /reclassified wherever necessary, to make them comparable.
- At the Extra Ordinary General Meeting held on 14/11/2024 pursuant to Notice dated 23/10/2024, the Shareholders have passed Special Resolutions and approved to issue 9853000 Equity Shares on Preferential Basis to proposed allottees at Rs. 32/- (Including Premium of Rs. 22/- Per Share) for consideration in cash / consideration other than cash.

For BACIL PHARMA LTD.




Mehul Hasmukhbhai Shah
Chairman & Director
DIN: 10753865
Place: Mumbai
Date: 21/01/2025

**Independent Auditor's Review Report on the Quarter and Nine Months Ended 31st December 2024
Unaudited Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015, as amended.**

To the Board of Directors
BACIL PHARMA LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of BACIL PHARMA LIMITED (the "Company") for the Quarter and Nine Months ended 31st December 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. Company's Board of Directors responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Emphasis of Matter**
The company has extended loans and advances to various parties, which are still outstanding as of the report date. However, due to the lack of confirmation, we are unable to express an opinion on the nature and recoverability of these loans and advances.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Laxmikant Kabra & Co LLP

Chartered Accountants

Firm Reg. No.: 117183W/ W100736



CA Siddhant Kabra

Partner

Membership No.: 193348



Place: Thane

Date: 21st January 2025

UDIN: 25193348BMHXVG7394